Wegovy vs Saxenda: Cost, Access, and Which Works Better for Women

The Bottom Line on Efficacy: How Much Weight Do You Actually Lose?

Wegovy outperforms Saxenda on weight loss by a significant margin in their respective key trials, though no direct head-to-head randomized controlled trial comparing the two drugs has been published.

In STEP-1, adults without diabetes receiving semaglutide 2.4 mg lost a mean of 14.9% of body weight over 68 weeks, compared with 2.4% on placebo. In SCALE Obesity and Prediabetes, liraglutide 3 mg produced a mean weight loss of 8.0% over 56 weeks, versus 2.6% on placebo. Because these trials used different populations, different durations, and different endpoints, you cannot treat the difference as a clean head-to-head result. The pattern across all GLP-1 comparative analyses does consistently favor semaglutide, but keep that caveat in mind.

What Does That Mean in Real Pounds?

For a woman weighing 220 lb (100 kg):

• Wegovy at 14.9%: approximately 33 lb lost
• Saxenda at 8.0%: approximately 18 lb lost

The gap narrows in people who do not tolerate the full maintenance dose of either drug, which is common. Nausea is the primary reason for dose reduction in both, and women report nausea at higher rates than men across GLP-1 trials, though sex-stratified data from STEP-1 and SCALE were not published as primary endpoints.

Responder Rates Matter Too

In STEP-1, 68.8% of semaglutide participants lost at least 10% of body weight, compared with 33.1% on liraglutide in SCALE. Roughly one in three women on Saxenda will lose 10% or more. With Wegovy, nearly two in three will reach that threshold. If your clinical goal is 10% weight loss to restore ovulation in PCOS or to reduce breast cancer recurrence risk, that difference in responder rate is clinically meaningful.

Cost and Insurance: The Real-World Access Picture

Both drugs carry high list prices, but their real-world costs differ considerably once you factor in insurance, manufacturer coupons, and supply issues.

List Price vs. What You Actually Pay

Saxenda's list price runs approximately $1,430 per month for the 18 mg/3 mL pens. Wegovy lists at approximately $1,349 per month for the 2.4 mg maintenance dose. Counterintuitively, Wegovy is cheaper at list price despite being the newer, more effective drug. That gap exists partly because Novo Nordisk positioned Wegovy aggressively against older obesity medications.

Without insurance, neither drug is affordable for most women on a median US income. Novo Nordisk offers a savings card for Wegovy that can reduce out-of-pocket cost to as low as $0/month for commercially insured patients and $650/month for those without commercial insurance. A comparable Saxenda savings program exists for eligible patients.

Insurance Coverage Differences

Saxenda has been on the market since 2014 and is more often included on established formularies, particularly for employer-sponsored plans. Wegovy received FDA approval in 2021 and initially struggled with formulary placement, though coverage has expanded substantially since 2023. The American Obesity Association estimates that fewer than 30% of commercially insured Americans had obesity medication coverage as of 2023, though that figure is rising.

Medicare Part D explicitly excluded anti-obesity medications until the Treat and Reduce Obesity Act was reintroduced. As of early 2025, Medicare still does not cover Wegovy or Saxenda for obesity alone, though Wegovy gained Medicare coverage for cardiovascular risk reduction following the SELECT trial results. If you have documented cardiovascular disease, ask your clinician specifically about this pathway.

Medicaid coverage varies by state. Several states, including New York and California, have added GLP-1 obesity medications to Medicaid formularies.

Supply and Availability

Wegovy faced prolonged shortage from mid-2022 through 2023 as demand outpaced manufacturing. Saxenda has generally been more consistently available at retail pharmacies, though spot shortages occur. When Wegovy is unavailable, some clinicians temporarily prescribe Ozempic (semaglutide 1 mg or 2 mg) as a workaround, though this is off-label for weight management and not equivalent to Wegovy's 2.4 mg dose.

Injection Schedule and Tolerability: Daily vs. Weekly

Saxenda requires a once-daily injection. Wegovy is once weekly. For most women, weekly dosing is a meaningful quality-of-life advantage.

Titration Schedules

Both drugs require slow dose escalation to minimize GI side effects:

Wegovy titration (semaglutide):

• Weeks 1-4: 0.25 mg weekly
• Weeks 5-8: 0.5 mg weekly
• Weeks 9-12: 1.0 mg weekly
• Weeks 13-16: 1.7 mg weekly
• Week 17 onward: 2.4 mg weekly (maintenance)

Saxenda titration (liraglutide):

• Week 1: 0.6 mg daily
• Week 2: 1.2 mg daily
• Week 3: 1.8 mg daily
• Week 4: 2.4 mg daily
• Week 5 onward: 3.0 mg daily (maintenance)

The FDA prescribing information for Wegovy recommends discontinuing if a patient cannot tolerate the 2.4 mg dose after titration. Saxenda's label similarly advises stopping if the patient has not lost at least 4% of body weight by week 16.

GI Side Effects and Women's Hormonal Context

Nausea, vomiting, diarrhea, and constipation are the most common adverse effects for both drugs. GI side effects tend to be worse during titration and often improve at maintenance dose.

Women experience a specific complication that male-default clinical discussions routinely miss: hormonal fluctuations across the menstrual cycle change gastric emptying. Progesterone, dominant in the luteal phase, slows gastric motility. This means GI side effects from both drugs may feel worse in the week before your period. Tracking your injection day relative to your cycle can help you anticipate this.

Women's Health Considerations by Life Stage

GLP-1 medications are not a one-size-fits-all treatment. Your hormonal status and reproductive plans should directly shape which drug you choose and when.

Reproductive Years and PCOS

PCOS affects an estimated 8-13% of women of reproductive age and is one of the leading reasons women in their 20s and 30s are prescribed GLP-1 medications. Weight loss of 5-10% can restore ovulation and reduce androgen levels in women with PCOS, and both semaglutide and liraglutide have been studied in this group.

A 2023 randomized trial published in Fertility and Sterility found that semaglutide improved menstrual regularity and androgen profiles in women with PCOS and obesity, though the trial used lower doses than Wegovy's 2.4 mg maintenance. Liraglutide has a longer evidence record in PCOS; a 2015 trial in Human Reproduction showed liraglutide 1.2 mg restored ovulation in a subset of anovulatory women with PCOS who had failed metformin.

If your primary goal is ovulation restoration for fertility, discuss the evidence base and timing with your reproductive endocrinologist before committing to either drug.

Perimenopause

Perimenopause typically spans the mid-40s into the early 50s and is characterized by falling estrogen, rising FSH, and increasingly irregular cycles. Weight gain accelerates during this transition, often shifting toward abdominal adiposity even without a change in caloric intake, due to declining estrogen's effect on fat distribution.

Both Wegovy and Saxenda address that weight gain directly. There is no published randomized trial of either drug specifically in perimenopausal women, which is a genuine evidence gap you deserve to know about. What we do know from STEP-1 subgroup data is that efficacy did not differ significantly by menopausal status, though the trial was not powered to detect subgroup differences.

A practical framework for perimenopausal women choosing between these two drugs:

1. If your primary complaint is vasomotor symptoms alongside weight gain, discuss whether menopausal hormone therapy (MHT) should be addressed concurrently. MHT and GLP-1 medications are not contraindicated together, and MHT may independently reduce abdominal fat accumulation.
2. If cardiovascular risk is elevated (hypertension, dyslipidemia, family history), Wegovy has the stronger cardiovascular outcomes data from the SELECT trial.
3. If daily structure helps with adherence, Saxenda's once-daily injection may fit better into an existing medication routine.

Postmenopause

Postmenopausal women carry the highest absolute cardiovascular risk in the female population. The SELECT trial, which enrolled participants with established cardiovascular disease, found that semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% versus placebo. This is the most compelling data point favoring Wegovy over Saxenda for postmenopausal women with existing CVD, as no equivalent cardiovascular outcomes trial exists for liraglutide 3 mg in the obesity indication.

Bone health is a relevant consideration postmenopause. Rapid weight loss from any cause can accelerate bone density loss. Both drugs are associated with modest reductions in bone mineral density in some studies, though a 2022 analysis in JAMA Network Open found no significant difference from placebo after accounting for fat mass changes. Ask your clinician about DEXA monitoring if you are already at fracture risk.

Pregnancy, Lactation, and Contraception Requirements

Both Wegovy and Saxenda are contraindicated in pregnancy. This section is non-negotiable reading if you are of reproductive age.

Pregnancy Safety Data

Animal reproductive studies with semaglutide showed embryo-fetal toxicity, including structural abnormalities, at doses producing exposures overlapping with human therapeutic levels. The FDA label for Wegovy states that use during pregnancy may cause fetal harm and advises discontinuation when pregnancy is detected.

Human data are limited. Case reports and registry data (primarily from the lower-dose Ozempic formulation used in type 2 diabetes) have not established a definitive teratogenic pattern in humans, but the dataset is small and the animal data are concerning enough to support avoiding use entirely during pregnancy.

The FDA label for Saxenda carries the same warning. Animal studies with liraglutide showed reduced fetal weight, early embryonic death, and skeletal and visceral abnormalities.

How Long Before Trying to Conceive Should You Stop?

Semaglutide has a half-life of approximately 7 days. Standard guidance, consistent with ACOG's approach to medications with long half-lives, is to stop Wegovy at least 2 months before attempting conception. This allows approximately 10 half-lives for drug clearance.

Liraglutide has a shorter half-life of roughly 13 hours, so Saxenda clears faster. Most clinicians recommend stopping Saxenda at least 1 month before attempting conception, though stopping earlier is safer.

If you are on either drug and your contraception is not reliable, discuss this with your prescriber. GLP-1 medications may reduce the absorption of oral contraceptives by slowing gastric emptying. The FDA label for semaglutide specifically notes this interaction and recommends switching to a non-oral contraceptive method or using a backup method for 4 weeks after each dose escalation step.

Lactation

Neither drug has adequate human lactation data. Semaglutide is a large peptide molecule and is unlikely to transfer into breast milk in clinically significant amounts, but this has not been formally studied. The NIH LactMed database classifies both semaglutide and liraglutide as having insufficient human data to assess risk. Given the lack of data and the non-urgent nature of weight management during lactation, most clinicians advise waiting until breastfeeding is complete before starting either drug.

Who Is a Better Candidate for Wegovy vs. Saxenda?

Your history, goals, and life stage should drive this decision more than the efficacy numbers alone.

Wegovy May Be the Better Fit If You:

• Have a BMI >30 (or >27 with a weight-related condition) and need maximum weight loss to achieve a specific clinical goal, such as bariatric surgery qualification, ovulation restoration in PCOS, or knee replacement candidacy
• Have established cardiovascular disease and are postmenopausal (SELECT trial data applies)
• Prefer once-weekly injections for adherence
• Have commercial insurance that covers Wegovy or qualify for the savings card program

Saxenda May Be the Better Fit If You:

• Have tried semaglutide and could not tolerate GI side effects at higher doses (some women do better with liraglutide's pharmacokinetic profile)
• Need a drug that clears faster if pregnancy is a near-term possibility (shorter half-life)
• Have Saxenda on formulary when Wegovy is not covered or is on backorder
• Are in a state where Medicaid covers Saxenda but not Wegovy

Neither Drug Is Appropriate If You:

• Are pregnant or planning pregnancy in the next 2 months (Wegovy) or 1 month (Saxenda)
• Are currently breastfeeding
• Have a personal or family history of medullary thyroid carcinoma or MEN2 (contraindicated for both drugs per their FDA labels)
• Have a history of pancreatitis (use with caution; discuss with your clinician)

Can You Switch Between the Two Drugs?

Switching from Saxenda to Wegovy, or vice versa, is done in clinical practice but has no standardized protocol from a randomized trial.

The most common direction is Saxenda to Wegovy, often because a woman has had partial response to liraglutide and wants to attempt greater weight loss. Clinicians typically stop Saxenda and start the Wegovy titration from the lowest dose (0.25 mg weekly), rather than attempting dose equivalence, because the two drugs have different receptor binding characteristics and potencies.

Switching from Wegovy to Saxenda is less common and usually driven by cost, supply issues, or tolerability. Because semaglutide is more potent, women who switch often find Saxenda provides less appetite suppression. Some experience rebound weight gain within weeks of switching.

The Endocrine Society's obesity pharmacotherapy guidelines do not address GLP-1-to-GLP-1 switching directly, which is a genuine clinical evidence gap.

A Note on the Evidence Gap for Women

Women were included in both STEP-1 and SCALE, but neither trial published primary results stratified by sex, menopausal status, or hormonal contraceptive use. STEP-1 enrolled approximately 75% women, which is encouraging, but sex-disaggregated analyses on weight loss magnitude, side effect rates, and cardiovascular outcomes remain sparse in the published literature.

The NIH's 1993 mandate to include women in federally funded research improved inclusion but did not require sex-stratified reporting. As a result, your clinician is often extrapolating from a mixed-sex dataset. Knowing this helps you ask better questions: "Was this subgroup analysis published?" and "Is there any data specifically in perimenopausal or postmenopausal women?"